Everett, Brendan M.

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine

Atherosclerosis and Cardiovascular DiseasesLipoproteins and Cardiovascular Health

Cited by 1,317

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 749

Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure

Everett, B. M., Cornel, J. H., Lainscak, M., Anker, S. D., Abbate, A., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2019) · Circulation

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 658

2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 473

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 466

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)

Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 461

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal

Atherosclerosis and Cardiovascular DiseasesInflammatory Biomarkers in Disease Prognosis

Cited by 368

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study

Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 319

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Cefalu, W. T., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M. L., Morris, P. B., et al. (2018) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 300

6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 172

Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese

Lubitz, S. A., Lunetta, K. L., Lin, H., Arking, D. E., Trompet, S., Li, G., Krijthe, B. P., Chasman, D. I., Barnard, J., Kleber, M. E., et al. (2014) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesGenetic Associations and Epidemiology

Cited by 148

Novel antiatherosclerotic therapies

Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology

Atherosclerosis and Cardiovascular DiseasesLipoproteins and Cardiovascular Health

Cited by 145

Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes

Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 144

Novel genetic markers improve measures of atrial fibrillation risk prediction

Everett, B. M., Cook, N. R., Conen, D., Chasman, D. I., Ridker, P. M., & Albert, C. M. (2013) · European Heart Journal

Atrial Fibrillation Management and OutcomesGenetic Associations and Epidemiology

Cited by 141

Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial

Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., & Ridker, P. M. (2009) · JAMA

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 117

Physical Activity and the Risk of Incident Atrial Fibrillation in Women

Everett, B. M., Conen, D., Buring, J. E., Moorthy, M. V., Lee, I.-M., & Albert, C. M. (2011) · Circulation: Cardiovascular Quality and Outcomes

Atrial Fibrillation Management and OutcomesPhysical Activity and Health

Cited by 116

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Management and Research

Cited by 108

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 107

Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease

Patorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 103

13. Older Adults: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 87

16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 80

Targeting Inflammation to Reduce Residual Cardiovascular Risk

Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports

Atherosclerosis and Cardiovascular DiseasesLipoproteins and Cardiovascular Health

Cited by 65

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study

Fralick, M., Kim, S. C., Schneeweiss, S., Everett, B. M., Glynn, R. J., & Patorno, E. (2020) · BMJ

Diabetes Treatment and ManagementDiabetic Foot Ulcer Assessment and Management

Cited by 63

Trends in aggregate use and associated expenditures of antihyperglycemic therapies among US Medicare beneficiaries between 2012 and 2017.

Sumarsono, A., Everett, B. M., McGuire, D. K., Fonarow, G. C., Butler, J., Pandey, A., & Vaduganathan, M. (2020) · JAMA Internal Medicine

Diabetes Treatment and ManagementDiversity and Career in Medicine

Cited by 21